Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 07/27 08:35:24 pm
81.929 EUR   -0.49%
07/26 SANOFI : Pasteur appoints new GM for Korea office
07/26SANOFI SA : half-yearly earnings release
07/26 SANOFI : Pasteur Korea elects new CEO
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CEST

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07/26 SANOFI : Pasteur appoints new GM for Korea office
07/26SANOFI SA : half-yearly earnings release
07/26 SANOFI : Pasteur Korea elects new CEO
07/25 SANOFI : Rich fly to Singapore for lifesaving dengue vaccine; poor helpless due ..
07/23 SANOFI : Judicial Panel on Multidistrict Litigation Issues Order on Taxotere
07/22 SANOFI : Regeneron Receive Positive CHMP Opinion for Dupixent (dupilumab) to Tre..
07/22 SANOFI : MSDs Lantus biosimilar given conditional FDA approval
07/22 SANOFI INDIA : Competition Commission of India rejects unfair business practices..
07/21 SANOFI : Annual fundraiser honors nonprofits
07/21 SANOFI : Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupil..
More news
News from SeekingAlpha
01:26p THE 'BEST BALANCE SHEETS' PORTFOLIO : LabCorp
07/25 Samsung Leaps Into Its First U.S. Biosimilars Battle
07/24 Boulder Growth & Income Fund Is At Least 5% Overvalued And A Poor Long-Term H..
07/23 Tracking Ken Fisher'S Fisher Asset Management Portfolio - Q2 2017 Update
07/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 23, 2017
Financials (€)
Sales 2017 36 412 M
EBIT 2017 9 526 M
Net income 2017 7 919 M
Debt 2017 4 789 M
Yield 2017 3,70%
P/E ratio 2017 13,32
P/E ratio 2018 17,16
EV / Sales 2017 2,98x
EV / Sales 2018 2,86x
Capitalization 103 798 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,0 €
Spread / Average Target 4,5%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI7.06%121 857
JOHNSON & JOHNSON14.47%352 757
NOVARTIS7.69%222 032
ROCHE HOLDING LTD.4.08%220 038
PFIZER1.91%195 864
MERCK AND COMPANY4.98%169 033